A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Trial Profile

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate384
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Oct 2017 This trial has been completed in Austria, according to European Clinical Trials Database.
    • 19 Jan 2017 This trial was completed in Ireland, according to European Clinical Trials Database.
    • 24 Sep 2016 Planned number of patients changed from 620 to 640.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top